A phase II/III trial of IkT 001Pro for treatment of pulmonary arterial hypertension

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 21 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Nov 2024 According to an Inhibhikase Therapeutics media release, company announced that they have Closed up to $275 million financing in October 2024. The financing will fund execution of this trial in Pulmonary Arterial Hypertension (PAH).
14 Nov 2024 According to an Inhibhikase Therapeutics media release, the Company received its Study May Proceed letter on September 9, 2024.
21 Oct 2024 According to an Inhibhikase Therapeutics media release, company announced the closing of a private placement of approximately $110 Million. The financing will fund execution of the Phase 2b 702 trial in Pulmonary Arterial Hypertension (PAH).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com